BioAgilytix, a provider of large molecule bioanalytical testing services, has acquired Cambridge Biomedical, a CRO specializing in large molecule bioanalysis. The transaction expands BioAgilytix’s global footprint into the Cambridge, MA biotech hub, and adds capacity with Cambridge Biomedical’s CLIA-certified, CAP-accredited, and GLP-compliant facility and GxP labs in Durham, NC and Hamburg, Germany. The acquisition also adds seasoned bioanalytical scientists enhancing BioAgilytix’s expertise in...